Tools / Trials and research CALCRL: Calcitonin gene-related peptide type 1 receptor A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
G protein-coupled receptor which specificity is determined by its interaction with receptor-activity-modifying proteins (RAMPs).
Drugs that act on it : 10 Approved : 5 In phases 1 to 3 : 5 Sponsors : 6 Who Is On It, and How Far Along Every drug ChEMBL records acting on CALCRL, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Small molecule Antibody Protein or peptideApproved5 Rimegepant Rimegepant SponsorPfizer ModalitySmall molecule ActionAntagonist Open trials37 Atogepant Atogepant SponsorAbbVie ModalitySmall molecule ActionAntagonist Open trials16 Erenumab Erenumab SponsorAmgen ModalityAntibody ActionAntagonist Open trials14 Ubrogepant Ubrogepant SponsorAbbVie ModalitySmall molecule ActionAntagonist Open trials6 Zavegepant Zavegepant SponsorPfizer ModalitySmall molecule ActionAntagonist Open trials5 Phase 31 Telcagepant Telcagepant SponsorMerck & Co. (MSD) ModalitySmall molecule ActionAntagonist Open trials0 Phase 24 BI-44370 BI-44370 SponsorBoehringer Ingelheim Pharmaceuticals ModalitySmall molecule ActionAntagonist Open trials0 Davalintide Davalintide SponsorAstraZeneca Pharmaceuticals ModalityProtein or peptide ActionAgonist Open trials0 MK3207 MK3207 SponsorMerck & Co. (MSD) ModalitySmall molecule ActionAntagonist Open trials0 Olcegepant Olcegepant SponsorBoehringer Ingelheim Pharmaceuticals ModalitySmall molecule ActionAntagonist Open trials0
Modalities Modalities Share Copy link Download image (PNG)Drugs on this target by ChEMBL molecule type.
Small molecule 8 80%Small molecule Count8 Share80% Antibody 1 10%Antibody Count1 Share10% Protein or peptide 1 10%Protein or peptide Count1 Share10%
The Landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 10 act as: Calcitonin gene-related peptide type 1 receptor antagonist; the rest name their own mechanism.
Open Trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 31 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals Rimegepant Not applicable Not yet recruiting Chinese PLA General Hospital 2026-11-05 Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations Rimegepant — Active, not recruiting Pfizer 2026-10-30 Acute Treatment of Vestibular Migraine by Rimegepant Rimegepant Phase 4 Recruiting Wensheng Qu 2026-10-13 A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of Migraine Zavegepant Not applicable Not yet recruiting American Center for Psychiatry and Neurology 2026-10-06 Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy Rimegepant Phase 1 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2026-09-22 Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) Erenumab Phase 1 Not yet recruiting M.D. Anderson Cancer Center 2026-09-21 Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine Rimegepant — Enrolling by invitation Nordlandssykehuset HF 2026-09-21 Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine Atogepant Phase 4 Not yet recruiting Konrad Peter Weber 2026-09-17 Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Rimegepant Phase 2 Not yet recruiting Shanghai Zhongshan Hospital 2026-09-10 Rimegepant For Endometriosis Pain Rimegepant Phase 2 Not yet recruiting Mayo Clinic 2026-08-31 A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study Rimegepant Phase 2 Not yet recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-07 Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache Zavegepant Phase 2 Not yet recruiting The University of Texas Health Science Center, Houston 2026-07-20 Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom Atogepant — Not yet recruiting AbbVie 2026-07-08 A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department Zavegepant Phase 1 Recruiting University of South Florida 2026-06-25 Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Atogepant, Erenumab Phase 4 Not yet recruiting Stanford University 2026-06-17 Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease Erenumab Early phase 1 Recruiting Xuanwu Hospital, Beijing 2026-01-07 Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks Ubrogepant — Recruiting AbbVie 2025-12-30 Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine Atogepant, Erenumab — Recruiting Hospital Universitari Vall d'Hebron Research Institute 2025-09-08 i-NEED: NEw migrainE Drugs Database Atogepant, Erenumab — Recruiting IRCCS San Raffaele Roma 2025-08-05 A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine Zavegepant Phase 1 Recruiting Pfizer 2025-05-29 Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study Atogepant Phase 4 Recruiting Mayo Clinic 2025-05-14 Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine Atogepant — Recruiting IRCCS National Neurological Institute "C. Mondino" Foundation 2025-03-18 A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years Atogepant Phase 3 Recruiting AbbVie 2025-02-05 Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies Erenumab — Active, not recruiting Fundación de Investigación Biomédica - Hospital Universitario de La Princesa 2024-06-14 Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine Ubrogepant Phase 3 Active, not recruiting AbbVie 2024-05-16 Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications Zavegepant Phase 4 Recruiting Mayo Clinic 2024-05-07 Migraine Medication Effects on Urinary Symptoms Erenumab, Ubrogepant — Enrolling by invitation The Cleveland Clinic 2024-01-19 Aimovig Pregnancy Exposure Registry Erenumab — Recruiting Amgen 2023-11-29 Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy Ubrogepant — Recruiting AbbVie 2021-12-15 Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) Ubrogepant Phase 3 Enrolling by invitation AbbVie 2021-11-19 Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) Ubrogepant Phase 3 Recruiting AbbVie 2021-11-18
Show all 31Diseases Most Associated With It Open Targets association score, 0 to 1; all associations
Lymphatic malformation 8 0.41
Hypertensive disorder 0.40
Non-immune hydrops fetalis 0.37
Hyperprolactinemia 0.37
Tachycardia 0.35
Coronary artery disorder 0.30
Obesity disorder 0.30
Cancer 0.27
Non-alcoholic fatty liver 0.26
Genes and Related Targets Complexes and families that share a gene with this target
Genes CALCRL Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3798 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q16602 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets